Expert NetworkExpert InterviewINCY

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the recent approval of Zynyz (Retifanlimab) from Incyte in merkel cell carcinoma (MCC).

Executed on:Apr 19, 2023 10:30 AM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Moffitt Cancer Center
  • Chief Academic Officer and Director of Regional Therapies at Moffitt Cancer Center; Chair on the Department of Oncologic Sciences at University of South Florida Morsani College of Medicine; Professor of Surgery at University of South Florida Morsani College of Medicine
  • Manages 20-35 patients with metastatic uveal melanoma
  • Research and clinical interests include the regional therapy treatment of cutaneous melanoma, non-melanoma skin cancers and soft tissue sarcomas; Also the director of regional therapies in the cutaneous oncology department 

Interview Goal

Discuss the current SoC for MCC and the label for Zynyz. 

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.